Description
Trade name:
Miflonide breezhaler 400 mсg, inhalation powder, 60 caps + device
Compound:
Each hard capsule for inhalation contains:
Budesonide 400 mcg
Excipients:
Lactose monohydrate.
Properties:
Glucocorticosteroid with pronounced local anti-inflammatory and anti-allergic effects.
Budesonide restores the patient’s sensitivity to bronchodilators, allowing a reduction in the frequency of their use, reduces swelling of the bronchial mucosa, mucus production, sputum formation and reduces airway hyperreactivity. Increases mucociliary transport. It is well tolerated during long-term treatment, does not have mineralocorticoid activity.
Indications:
Intended for long-term use in bronchial asthma to prevent attacks.
Chronic obstructive bronchitis for which treatment with glucocorticoids is indicated.
Method of administration and dosage:
Miflonide Breezhaler hard capsules should only be used with the Miflonide Breezhaler inhaler and only for inhalation.
The dosage of the drug is selected strictly individually. The drug is intended for daily use. When changing the inhaler, it may be necessary to recalculate the dose.
When treating adult patients, the initial minimum dose is 200 mcg. The average therapeutic dose is 200-400 mcg 2 times a day. When switching from tablet corticosteroids to inhaled ones, the daily dose can be increased, if necessary, to 1600 mcg in 2-4 doses.
Contraindications:
Hypersensitivity to the drug.
Children under 6 years of age.
Tuberculosis of the lungs in the acute phase.
Precautions:
The drug is not intended for the relief of acute attacks of bronchial asthma and asthmatic status.
Use with caution in patients with pulmonary tuberculosis; fungal, bacterial, parasitic and viral infections of the respiratory system; liver cirrhosis; during pregnancy; during lactation.
Side effects:
Systemic effects may occur with inhaled GCS, especially with long-term high-dose treatment. The likelihood of such effects is significantly lower than with oral GCS.
From the respiratory system: often – irritation and dryness of the mucous membrane of the pharynx, hoarseness, cough. With inhalation therapy, there is a risk of paradoxical bronchospasm with a rapid increase in dyspnea after administration of the dose.
From the digestive system: often – candidal stomatitis, dryness of the oral mucosa, unpleasant taste sensations; rarely – nausea, esophageal candidiasis.
From the nervous system: rarely – nervousness, excitability, depression, behavioral disorders, headache,
Allergic reactions: rare – immediate and delayed hypersensitivity reactions (including rash, contact dermatitis, urticaria, angioedema and bronchospasm),
From the skin: rarely – the appearance of skin bruises or thinning of the skin.
From the endocrine system: with long-term treatment in high doses, suppression of the function of the adrenal cortex, growth retardation in children and adolescents, decreased bone mineral density, cataracts, and glaucoma are possible.
Storage method:
Store at room temperature not exceeding 25 degrees.
